Evidence map›Paper›PMID 41376835›Full record

ArticleClinical case reports2025

A Case of AL Amyloidosis With Hepatomegaly as the Main Clinical Manifestation.

Shuchen Dong, Renjun Lv, Wei Wang, Guoling Gao, Mingfeng Zhao, Xingbin Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Shuchen DongDepartment of Gastroenterology and Hepatology Binzhou Medical University Hospital Binzhou Shandong Province China.ORCID https://orcid.org/0009-0008-1771-5666
Renjun LvDepartment of Geriatrics Shandong Provincial Hospital Affiliated to Shandong First Medical University Jinan Shandong Province China.
Wei WangDepartment of Gastroenterology and Hepatology Binzhou Medical University Hospital Binzhou Shandong Province China.
Guoling GaoDepartment of Gastroenterology and Hepatology Binzhou Medical University Hospital Binzhou Shandong Province China.
Mingfeng ZhaoDepartment of Pathology Binzhou Medical University Hospital Binzhou Shandong Province China.
Xingbin MaDepartment of Gastroenterology and Hepatology Binzhou Medical University Hospital Binzhou Shandong Province China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Light chain (AL) amyloidosis presenting predominantly with hepatomegaly is a rare and frequently misdiagnosed condition. While clinical features are non-specific, elevated ALP/GGT should raise suspicion. A liver biopsy remains the gold standard for diagnosis. Although there is no disease-specific therapy for hepatic amyloidosis, timely chemotherapy initiation-particularly monoclonal antibody-based regimens-can significantly improve prognosis and lead to symptom resolution.

Indexed as

AL amyloidosishepatomegalyliver biopsyprognosis

Identifiers

PMID41376835
PMCPMC12685610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.